{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:05:45Z","timestamp":1790233545268,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025A1515010664"],"award-info":[{"award-number":["2025A1515010664"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901854"],"award-info":[{"award-number":["81901854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejrad.2026.113082","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:50:14Z","timestamp":1784271014000},"page":"113082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Combination of programmed death protein-1 inhibitor improves the efficacy of transarterial chemoembolization plus lenvatinib for unresectable intermediate-stage hepatocellular carcinoma: a real-world multi-center retrospective study"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-9354","authenticated-orcid":false,"given":"Jiayan","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gefan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.ejrad.2026.113082_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"2022","key":"10.1016\/j.ejrad.2026.113082_b0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejrad.2026.113082_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101567","article-title":"The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO\/World Congress on Gastrointestinal Cancer, Barcelona, 2022","volume":"8","author":"Ducreux","year":"2023","journal-title":"ESMO. Open"},{"key":"10.1016\/j.ejrad.2026.113082_b0020","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma, J. Hepatol. 16 (2024) S0168-8278(24)02508-X. Doi: 10.1016\/j.jhep.2024.08.028.","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"10.1016\/j.ejrad.2026.113082_b0025","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s12029-023-00940-5","article-title":"Stereotactic body radiation therapy with or without transarterial chemoembolization versus transarterial chemoembolization alone in early-stage hepatocellular carcinoma: a systematic review and meta-analysis","volume":"54","author":"Dumago","year":"2023","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ejrad.2026.113082_b0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/carcin\/bgad052","article-title":"The current landscape of therapies for hepatocellular carcinoma","volume":"44","author":"Coffman-D'Annibale","year":"2023","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejrad.2026.113082_b0035","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.230727","article-title":"Contrast-enhanced US evaluation of hepatocellular carcinoma response to chemoembolization: a prospective multicenter trial","volume":"309","author":"Savsani","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2026.113082_b0040","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102386","article-title":"Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors","volume":"9","author":"Al-Toubah","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2026.113082_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110797","article-title":"The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma","volume":"132","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejrad.2026.113082_b0055","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.acra.2024.04.045","article-title":"Transarterial chemoembolization (TACE) combined with lenvatinib versus TACE alone in intermediate-stage hepatocellular carcinoma patients beyond up-to-seven criteria: a retrospective, propensity score-matched analysis","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.ejrad.2026.113082_b0060","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1186\/s12885-024-13199-1","article-title":"Effectiveness of sorafenib in treating intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization","volume":"24","author":"Ashour","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejrad.2026.113082_b0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.31557\/APJCP.2021.22.4.1217","article-title":"The impact of sorafenib in combination with transarterial chemoembolization on the outcomes of intermediate-stage hepatocellular carcinoma","volume":"22","author":"Kaibori","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.ejrad.2026.113082_b0070","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ejrad.2026.113082_b0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/hepr.13718","article-title":"Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study","volume":"51","author":"Rimini","year":"2021","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejrad.2026.113082_b0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113082_b0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000531377","article-title":"A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial","volume":"13","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ejrad.2026.113082_b0090","article-title":"Immunotherapy for hepatocellular carcinoma","volume":"6","author":"Childs","year":"2024","journal-title":"JHEP. Rep."},{"key":"10.1016\/j.ejrad.2026.113082_b0095","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2024.01.011","article-title":"Immunotherapy and transplantation for hepatocellular carcinoma","volume":"80","author":"Tabrizian","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejrad.2026.113082_b0100","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.3390\/curroncol30110711","article-title":"Advances in immunotherapy for hepatocellular carcinoma (HCC)","volume":"30","author":"Bicer","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0105","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1007\/s12094-024-03458-9","article-title":"Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1\/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"26","author":"Liang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0110","first-page":"3627","article-title":"Feasibility and safety of the clinical outcomes of TACE combined with lenvatinib and PD-1 blockades in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective exploratory study","volume":"17","author":"Sun","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.ejrad.2026.113082_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108634","article-title":"Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"257","author":"Wang","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejrad.2026.113082_b0120","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00330-019-06438-8","article-title":"A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation","volume":"30","author":"Ni","year":"2020","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejrad.2026.113082_b0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113082_b0130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in patients with recurrent intermediate-stage hepatocellular carcinoma: sorafenib plus TACE vs TACE alone randomized clinical trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0135","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.3390\/curroncol31100432","article-title":"Efficacy of atezolizumab plus bevacizumab-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma","volume":"31","author":"Moriyama","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0140","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3892\/ol.2020.11758","article-title":"Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: a multicenter cohort study using data mining analysis","volume":"20","author":"Shimose","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejrad.2026.113082_b0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","article-title":"Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study","volume":"15","author":"Fu","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.ejrad.2026.113082_b0150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000515865","article-title":"Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma","volume":"99","author":"Ando","year":"2021","journal-title":"Oncology"},{"key":"10.1016\/j.ejrad.2026.113082_b0155","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3390\/cancers15102738","article-title":"Targeting hypoxia-inducible factor-1\u03b1 for the management of hepatocellular carcinoma","volume":"15","author":"Huynh","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.ejrad.2026.113082_b0160","first-page":"e105","article-title":"Predictive value of recurrence for serum hypoxia inducible factor-1\u03b1 C-reaction protein in hepatocellular carcinoma patients after transcatheter arterial chemoembolization","volume":"52","author":"Jing","year":"2015","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.ejrad.2026.113082_b0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00432-016-2237-x","article-title":"Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1\u03b1 for hepatocellular carcinoma: a preliminary study of rat model","volume":"143","author":"Ni","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/imm.13853","article-title":"Hypoxic tumour-derived exosomal miR-1290 exacerbates the suppression of CD8+ T cells by promoting M2 macrophage polarization","volume":"173","author":"Yang","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.ejrad.2026.113082_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112282","article-title":"Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape","volume":"138","author":"Shang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejrad.2026.113082_b0180","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.21037\/tcr-22-253","article-title":"Novel hypoxia features with appealing implications in discriminating the prognosis, immune escape and drug responses of 947 hepatocellular carcinoma patients","volume":"11","author":"Luan","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ejrad.2026.113082_b0185","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240, a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0195","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113082_b0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.47995","article-title":"Locoregional therapies for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejrad.2026.113082_b0205","article-title":"TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejrad.2026.113082_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.945915","article-title":"Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: a propensity score matching study","volume":"12","author":"Guo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejrad.2026.113082_b0215","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00432-021-03767-4","article-title":"Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X26004304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X26004304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:41:21Z","timestamp":1790232081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X26004304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"alternative-id":["S0720048X26004304"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2026.113082","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of programmed death protein-1 inhibitor improves the efficacy of transarterial chemoembolization plus lenvatinib for unresectable intermediate-stage hepatocellular carcinoma: a real-world multi-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2026.113082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113082"}}